Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies

The incidence rate of invasive mucormycosis (IM) in patients with hematological malignancies (HMs) is increasing year by year, ranging from 0.07% to 4.29%, and the mortality rate is mostly higher than 50%. With the ongoing pandemic of COVID-19, COVID-19-associated mucormycosis (CAM) also became a gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Nuobing, Zhang, Lining, Feng, Sizhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219352/
https://www.ncbi.nlm.nih.gov/pubmed/37233303
http://dx.doi.org/10.3390/jof9050592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219352/
https://www.ncbi.nlm.nih.gov/pubmed/37233303
http://dx.doi.org/10.3390/jof9050592

Ejemplares similares